Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, Status and Forecast 2020-2026

May 2020 | 90 pages | ID: G1C89468B5E5EN
QYResearch

Abstracts

This report focuses on the global Hormone Refractory Prostate Cancer (HRPCA) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hormone Refractory Prostate Cancer (HRPCA) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

• Astellas Inc
• Sanofi S.A
• Dendreon Corporation, Bayer AG
• Johnson & Johnson
• ...

Market segment by Type, the product can be split into

• Chemotherapy
• Hormonal Therapy
• Immunotherapy
• Radiation Therapy
• Surgery

Market segment by Application, split into

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Hormone Refractory Prostate Cancer (HRPCA) status, future forecast, growth opportunity, key market and key players.
• To present the Hormone Refractory Prostate Cancer (HRPCA) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Hormone Refractory Prostate Cancer (HRPCA) are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
1.4 Market Analysis by Type
  1.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Chemotherapy
  1.4.3 Hormonal Therapy
  1.4.4 Immunotherapy
  1.4.5 Radiation Therapy
  1.4.6 Surgery
1.5 Market by Application
  1.5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Ambulatory Surgical Centers
  1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2015-2026)
2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Regions
  2.2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Share by Regions (2015-2020)
  2.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Hormone Refractory Prostate Cancer (HRPCA) Market Growth Strategy
  2.3.6 Primary Interviews with Key Hormone Refractory Prostate Cancer (HRPCA) Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Market Size
  3.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2015-2020)
  3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2015-2020)
  3.1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio
  3.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2019
3.3 Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Area Served
3.4 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
3.5 Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2015-2020)
4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2021-2026)

5 HORMONE REFRACTORY PROSTATE CANCER (HRPCA) BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)
5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
6.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in North America (2019-2020)
6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
6.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
7.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in Europe (2019-2020)
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
7.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

8 CHINA

8.1 China Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
8.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in China (2019-2020)
8.3 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
8.4 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
9.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in Japan (2019-2020)
9.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
9.4 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
10.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
10.4 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

11 INDIA

11.1 India Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
11.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in India (2019-2020)
11.3 India Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
11.4 India Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2015-2020)
12.2 Hormone Refractory Prostate Cancer (HRPCA) Key Players in Central & South America (2019-2020)
12.3 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
12.4 Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Astellas Inc
  13.1.1 Astellas Inc Company Details
  13.1.2 Astellas Inc Business Overview and Its Total Revenue
  13.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction
  13.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020))
  13.1.5 Astellas Inc Recent Development
13.2 Sanofi S.A
  13.2.1 Sanofi S.A Company Details
  13.2.2 Sanofi S.A Business Overview and Its Total Revenue
  13.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction
  13.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
  13.2.5 Sanofi S.A Recent Development
13.3 Dendreon Corporation, Bayer AG
  13.3.1 Dendreon Corporation, Bayer AG Company Details
  13.3.2 Dendreon Corporation, Bayer AG Business Overview and Its Total Revenue
  13.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction
  13.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
  13.3.5 Dendreon Corporation, Bayer AG Recent Development
13.4 Johnson & Johnson
  13.4.1 Johnson & Johnson Company Details
  13.4.2 Johnson & Johnson Business Overview and Its Total Revenue
  13.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction
  13.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
  13.4.5 Johnson & Johnson Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Hormone Refractory Prostate Cancer (HRPCA) Key Market Segments
Table 2. Key Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
Table 3. Ranking of Global Top Hormone Refractory Prostate Cancer (HRPCA) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Hormonal Therapy
Table 7. Key Players of Immunotherapy
Table 8. Key Players of Radiation Therapy
Table 9. Key Players of Surgery
Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2015-2020)
Table 14. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Hormone Refractory Prostate Cancer (HRPCA) Market Growth Strategy
Table 20. Main Points Interviewed from Key Hormone Refractory Prostate Cancer (HRPCA) Players
Table 21. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2015-2020) (Million US$)
Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players (2015-2020)
Table 23. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2019)
Table 24. Global Hormone Refractory Prostate Cancer (HRPCA) by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
Table 27. Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Type (2015-2020)
Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2026)
Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application (2015-2020)
Table 33. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 34. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application (2021-2026)
Table 35. North America Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 39. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 40. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 41. Europe Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 45. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 47. China Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 48. China Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 49. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 50. China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 51. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 52. China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 53. Japan Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 55. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 57. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 61. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 63. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 65. India Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 66. India Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 67. India Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 68. India Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 69. India Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 70. India Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Hormone Refractory Prostate Cancer (HRPCA) Market Share (2019-2020)
Table 73. Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2015-2020)
Table 75. Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2015-2020)
Table 77. Astellas Inc Company Details
Table 78. Astellas Inc Business Overview
Table 79. Astellas Inc Product
Table 80. Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020) (Million US$)
Table 81. Astellas Inc Recent Development
Table 82. Sanofi S.A Company Details
Table 83. Sanofi S.A Business Overview
Table 84. Sanofi S.A Product
Table 85. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020) (Million US$)
Table 86. Sanofi S.A Recent Development
Table 87. Dendreon Corporation, Bayer AG Company Details
Table 88. Dendreon Corporation, Bayer AG Business Overview
Table 89. Dendreon Corporation, Bayer AG Product
Table 90. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020) (Million US$)
Table 91. Dendreon Corporation, Bayer AG Recent Development
Table 92. Johnson & Johnson Company Details
Table 93. Johnson & Johnson Business Overview
Table 94. Johnson & Johnson Product
Table 95. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020) (Million US$)
Table 96. Johnson & Johnson Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Hormonal Therapy Features
Figure 4. Immunotherapy Features
Figure 5. Radiation Therapy Features
Figure 6. Surgery Features
Figure 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions: 2020 VS 2026
Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players in 2019
Figure 17. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2019
Figure 19. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Astellas Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
Figure 28. Sanofi S.A Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
Figure 30. Dendreon Corporation, Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
Figure 32. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2015-2020)
Figure 34. Bottom-up and Top-down Approaches for This Report
Figure 35. Data Triangulation
Figure 36. Key Executives Interviewed